Lysogene S.A. continues to strengthen its management team by attracting significant industry veterans with the appointment of Dr. Ralph Laufer as Chief Scientific Officer, effective May 2, 2018. Dr. Laufer is a highly experienced professional with a strong track record in drug discovery, preclinical development and CMC at Teva Pharmaceuticals and Merck Inc. He joins Lysogene's executive team, recently reinforced with Sophie Olivier as Chief Medical Officer (formerly at Wyeth), and Philippe Mendels-Flandre as Chief Operating Officer (formerly at Baxter/Baxalta).